Scholarly Activity

Neurology Publications

Scholarly journal articles and meeting abstracts authored by members of the Department of Neurology at Henry Ford Health.

Map of recent downloads

 



Neurology Articles

  • 10/1/2026 7:00 AM

    Multi-infarct dementia (MID) is a major subtype of vascular cognitive impairment, second only to Alzheimer's disease as a leading cause of dementia worldwide. Unlike neurodegenerative dementias, MID results from recurrent vascular insults, producing stepwise cognitive decline. Animal models have become indispensable for understanding MID mechanisms and testing therapies, yet no single model fully captures human disease complexity. This review synthesizes current knowledge of embolic, chronic cerebral hypoperfusion, hypertensive, and large animal models of MID. We compare methodological strategies, neuropathological features (including white matter injury, neuroinflammation, and blood-brain barrier disruption), and behavioral outcomes. Key limitations include poor replication of infarct heterogeneity, absence of comorbidities, and translational failures. Emerging directions such as multi-hit paradigms and mixed dementia models are discussed. We conclude that integrative, multifactorial models are essential for improving translational relevance and developing effective therapies.

  • 9/15/2026 7:00 AM

    BACKGROUND: Although the embolic stroke of undetermined source (ESUS) construct was proposed as a unifying concept for embolic-appearing strokes without an identified cause, it includes patients with diverse and often unrecognized underlying mechanisms. This study investigates the differential rate of recurrent stroke according to the completeness of neurodiagnostic testing in a diverse multicenter cohort.

    METHODS: This was a retrospective analysis of a multicenter observational cohort study (n=27 sites). ESUS was categorized into 3 groups: (1) established mechanism after further workup (ESUS-E), (2) comprehensive diagnostic workup without an identified cause (ESUS 2.0), and (3) no advanced workup. The primary outcome of recurrent ischemic stroke was compared between ESUS with established mechanism and ESUS 2.0 versus ESUS with no advanced workup and was assessed using adjusted Cox proportional hazards models.

    RESULTS: Among 2281 patients, the mean age was 65 years, and 50.1% were men. 694 (30.4%) classified as ESUS-E, 1,243 (54.5%) classified as ESUS-NAW, and 344 (15.1%) as ESUS 2.0. The ESUS 2.0 group had a significantly lower risk of recurrent stroke than both the group with ESUS with no advanced workup (adjusted hazard ratio [aHR], 0.31 [95% CI, 0.13-0.76]) and the group with ESUS with established mechanism (aHR, 0.35 [95% CI, 0.15-0.85]). Within the group with ESUS with established mechanism, cancer (aHR, 5.33 [95% CI, 2.09-13.63]) and nonstenosing atherosclerotic disease or arch atheroma (aHR, 3.40 [95% CI, 1.18-9.83]) were associated with significantly increased risk of recurrence when compared with the group with ESUS 2.0.

    CONCLUSIONS: These findings demonstrate a lower risk of recurrent stroke in patients classified as ESUS 2.0 than reported in prior ESUS trials and highlight the importance of age-appropriate advanced diagnostic evaluation.

    REGISTRATION: URL: https://www.clinicaltrials.gov. Identifier: NCT06398366.

  • 9/1/2026 7:00 AM

    MicroRNAs regulate neural stem cell function. Argonaute 2 protein, constituent of the RNA-induced silencing complex, plays an important role in regulating microRNA function for post-transcriptional gene silencing. Although Argonaute 2 and microRNAs are recognized as central regulators of RNA-induced silencing complex, their precise role in adult neural stem cell function has remained unclear. In particular, it was not known whether Argonaute 2 is required for sustaining neural stem cell proliferation, neurogenesis, and oligodendrogenesis in the adult brain, or how its loss might influence recovery after ischemic injury. The present study examined the effect of Argonaute 2 deletion in adult neural stem cells on neurogenesis and oligodendrogenesis. Adult transgenic mice with conditional and inducible ablation of Argonaute 2 in Ascl1-lineage neural stem cells exhibited the reduction of neurogenesis in the ventricular–subventricular zone of the lateral ventricle and in the subgranular zone of the dentate gyrus, as evidenced by a decrease in neural stem cell proliferation and neuroblast numbers. Argonaute 2 deletion also reduced oligodendrogenesis in the corpus callosum, as indicated by the reduction of oligodendrocyte progenitor cell proliferation and the number of mature oligodendrocytes. Additionally, deleting Argonaute 2 in adult neural stem cells of ischemic mice exacerbated impairments of sensorimotor and cognitive functions. Mechanistically, Argonaute 2 ablation in neural stem cells reduced the stability of mature microRNAs and downregulated genes involved in the Shh (Sonic Hedgehog), Notch, and TGFβ (transforming growth factor beta) signaling pathways, which regulate the functions of neural stem cells. Collectively, our study demonstrates that Argonaute 2 is essential for adult neural stem cell-mediated neurogenesis and oligodendrogenesis, with its deletion worsening recovery after ischemia. By revealing that Argonaute 2 stabilizes mature microRNAs, our work uncovers a novel mechanism of neural stem cell regulation and highlights Argonaute 2 as a potential therapeutic target for neurodegenerative and ischemic brain diseases.

  • 9/1/2026 7:00 AM

    BACKGROUND: The impact of internal carotid artery tortuosity on achieving first-pass effect in mechanical thrombectomy has been described; however, middle cerebral artery (MCA) tortuosity remains understudied. We investigated the association of MCA tortuosity with radiographic and functional outcome using quantitative and qualitative measures. METHODS: The ARISE II study (Analysis of Revascularization in Ischemic Stroke With EmboTrap) was used to identify patients with anterior circulation stroke. MCA tortuosity was calculated using the Inflection Count Metric by 2 readers blinded to the angiographic/clinical outcomes. The total cohort was trichotomized into 3 groups (A, B, and C) based on M1 tortuosity tertiles, with group A representing the lowest tertile and group C representing the highest tertile. The primary efficacy end point was the achievement of first-pass expanded Thrombolysis in Cerebral Ischemia reperfusion ≥2c. A good functional outcome was defined as a 90-day modified Rankin Scale score of 0 to 2. Baseline and procedural data were compared between groups. RESULTS: A total of 168 patients with M1 or M2 occlusion and measurable MCA tortuosity were identified. Patients in group C were more likely to have renal disease and hyperlipidemia, whereas patients in group A were more likely to have hypertension (P< 0.05). There were no significant differences in the National Institutes of Health Stroke Scale score at presentation or the Alberta Stroke Program Early Computed Tomography Score between groups. First-pass effect was more likely in group A than in groups B and C (51.8% versus 37.5% and 26.8%, respectively; P=0.024). The rate of final expanded Thrombolysis in Cerebral Ischemia reperfusion ≥2c was higher in group A (87.5%) versus in groups B and C (77.8% and 66%, respectively; P=0.026); achieving modified Rankin Scale score of 0 to 2 was more likely in group A (77.8%) versus in groups B and C (74.5% and 52.7%, respectively; P=0.008). There were no differences in distal emboli or symptomatic intracranial hemorrhage. First-pass effect and angiographic outcomes were consistent with standard angle of curvature tortuosity. CONCLUSIONS: Patients with higher MCA tortuosity were less likely to achieve first-pass effect, successful reperfusion, and good functional outcome at 90 days postmechanical thrombectomy for acute ischemic stroke.

  • 9/1/2026 7:00 AM

    IMPORTANCE: DNL343 is a brain-penetrant small molecule that acts as an activator of eukaryotic translation initiation factor 2B (eIF2b), designed to inhibit the integrated stress response. A prior phase 1B trial of DNL343 in amyotrophic lateral sclerosis (ALS) provided evidence of a favorable safety profile, central nervous system penetrance, and target engagement based on integrated stress response biomarkers in blood and cerebrospinal fluid.

    OBJECTIVES: To evaluate the safety and efficacy of a 200-mg formulation of DNL343 given once daily in individuals living with ALS.

    DESIGN, SETTING, AND PARTICIPANTS: DNL343 was evaluated as a regimen of the HEALEY ALS Platform Trial, a double-blind, multiregimen, placebo-controlled randomized clinical trial conducted at 74 centers in the US between May 24, 2023, and May 22, 2025. Eligible participants were randomized in a 3:1 ratio to receive DNL343 or matching placebo, with both groups enrolling concurrently. The analysis included shared randomized participants receiving placebo from an additional regimen.

    INTERVENTION: The study drug was administered for a placebo-controlled duration of 24 weeks.

    MAIN OUTCOMES AND MEASURES: The primary analysis was a bayesian shared parameter model of function and survival that provided an integrated estimate of the relative rate of disease progression among participants receiving DNL343 relative to placebo. The model had components for function and survival linked through an integrated estimate of disease slowing in treatment relative to controls across the 2 outcomes (denoted as the disease rate ratio [DRR]). Several safety, secondary, and exploratory end points were also evaluated.

    RESULTS: A total of 259 screenings were completed in this regimen; 249 participants met eligibility and were randomized to DNL343 (n = 186) and regimen-specific placebo (n = 63), with an additional 76 participants from a concurrent regimen receiving placebo included for a total of 139 shared placebo participants (325 participants, with 196 (60.3%) male and mean [SD] age of 59.3 [11.5] years). The estimated median DRR common to the ALS Functional Rating Scale-Revised and survival was 1.04 (95% credible interval, 0.83-1.32; probability of DRR < 1, 0.37). Secondary outcome measures were not statistically different between the DNL343 and placebo groups. Overall, the incidence rates of adverse events were similar in participants receiving DNL343 and placebo.

    CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, despite the relevance of the eIF2b activation pathway in ALS disease biology and supporting evidence of proof of mechanism and optimal dose selection in a prior phase 1B ALS clinical trial, 200-mg/d DNL343 did not show evidence of slowing disease progression in ALS, highlighting the need for alternative therapeutic approaches.

    TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05842941.

  • 8/18/2026 7:00 AM

    BACKGROUND: Alzheimer’s disease (AD) is characterized by the excessive accumulation of select proteins in the brain, associated with altered vascular function, glymphatic transport, cerebrospinal fluid (CSF) dynamics, and cerebral microstructure. Exosomes derived from cerebral endothelial cells (CEC-Exo) have been demonstrated to reduce vascular dysfunction, which may beneficially impact perivascular glymphatic clearance, and potentially, protein aggregates and the corresponding microstructural disruption. METHODS: We investigated the effect of CEC-Exo therapy on AD by assessing glymphatic transport, CSF motion, and microstructural integrity using magnetic resonance imaging (MRI), and measuring cognitive performance. TgF344-AD rats, at 12-months of age, were randomly treated with CEC-Exo (1×10(11) particles/intravenous injection) or saline twice-weekly for four consecutive weeks. MRI measurements, including dynamic 3D T1-weighted imaging with contrast agent and diffusion MRI (dMRI) with multiple b-values, were conducted for all rats at 13-months. Glymphatic function was evaluated with tracer-induced time signal curve (TSC), while microstructural state and CSF motion were assessed with parameters derived from dMRI acquired at high (dMRI(high-b)) and low (dMRI(low-b)) b-values, respectively. Cognitive performance was assessed by the Morris water maze (MWM) test. RESULTS: TSCs demonstrated significantly higher peak values in the olfactory bulb and whole brain in the CEC-Exo-treated group than in the saline-treated group. With the CEC-Exo treatment, a significantly increased MD(low-b), a measure of pseudorandom CSF motion derived from dMRI(low-b), was observed in the representative CSF-filled space. As revealed by dMRI(high-b)-derived parameters, CEC-Exo treatment resulted in significantly elevated axonal water fraction, fractional anisotropy, and Kurtosis in white matter, as well as significantly reduced mean diffusivity, axial diffusivity, and radial diffusivity in both white and gray matter in the AD brain. In the MWM test, CEC-Exo-treated rats spent a significantly greater percentage of time in the correct quadrant than did saline-treated rats. CONCLUSION: CEC-Exo treatment preserved glymphatic transport, CSF motion, and microstructural integrity in the AD brain, accompanied by a reduced cognitive decline. With a global therapeutic impact, the CEC-Exo therapy provides a novel strategy on the treatment of AD. Our data support the value of dMRI(low-b) as a clinically feasible imaging tool for assessing alterations in CSF dynamics that mediate perivascular glymphatic clearance.

  • 8/14/2026 7:00 AM

    Background/Objectives: Cognitive impairment and neurological dysfunction in Multiple Sclerosis are increasingly understood as consequences of altered brain network connectivity. Magnetoencephalography offers high temporal resolution for investigating functional connectivity patterns, which may underlie various clinical symptoms. This exploratory pilot study aims to characterize preliminary FC patterns at rest and during cognitive processing in MS patients with a high fatigue burden compared with healthy controls using MEG, complemented by a systematic review of existing MEG literature in MS. Methods: In this pilot study, MEG was utilized to investigate connectivity in MS patients and HCs. Data were acquired during resting-state and a digitized version of the Symbol Digit Modalities Test. A systematic review was also conducted following PRISMA guidelines to synthesize the current evidence on frequency-specific MEG connectivity in MS. Results: MS patients exhibited a connectivity pattern paralleling the directionality of neuronal slowing, described in the spectral power MS literature, during resting-state, characterized by reduced interhemispheric coherence in alpha and beta bands alongside region-specific increases in frontal-parietal and parietal-occipital alpha coherence, reflecting a bidirectional spatial reorganization. Conversely, during the SDMT task, the MS group demonstrated significant compensatory recruitment with increased coherence in theta and gamma bands (specifically in frontal and striatal circuits). The systematic review of 44 MEG studies corroborated these findings, highlighting a consistent trend of frequency-dependent dysconnectivity that aligns with clinical load and disease pathology. Conclusions: We found that in MS, network alterations are state-dependent, shifting from reduced connectivity at rest to increased coherence during cognitive effort. These preliminary findings suggest that MEG-based connectivity may serve as a functional neuroimaging biomarker of underlying network reorganization, for monitoring early cognitive disease progression in MS.

  • 7/16/2026 7:00 AM

    Lymphomas represent a biologically diverse group of B-, T-, and NK-cell malignancies, where challenges such as relapse, drug resistance, treatment-related toxicity, sanctuary-site disease, and variable antigen expression continue to impede therapeutic outcomes, despite significant advancements in immunotherapy. Nanomedicine presents a strategic approach to enhance drug delivery, target malignant lymphocytes or supportive microenvironmental cells, and integrate molecular imaging with therapy; however, the extent of clinical validation varies considerably across different platforms. This review provides an overview of nanotechnology-enabled strategies for the treatment of lymphoma, including antibody–drug and radioimmunoconjugates, liposomal and albumin-based drug carriers, aptamer-guided systems, photothermal and photodynamic platforms, exosomes and liquid-biopsy nanoprobes, mRNA/lipid nanoparticle strategies, and AI-guided design. We highlight lymphoma-specific delivery challenges, such as the presence of bulky nodal disease, circulating malignant cells, marrow and CNS involvement, splenic and hepatic sequestration, antigen sinks, and the limited reliability of passive enhanced permeability and retention. Approved and guideline-supported examples are differentiated from active clinical trials and preclinical-only concepts to provide a clinically oriented interpretation of the current evidence and future translational priorities.

  • 7/14/2026 7:00 AM

    Huntington's disease (HD) is a rare, autosomal dominant neurodegenerative disorder caused by a pathogenic CAG expansion in the huntingtin gene, classically characterized by a triad of cognitive, psychiatric, and motor symptoms. Involuntary movements known as chorea are the most notable feature of HD. Despite the negative impact chorea can have on many aspects of day-to-day life, pharmacologic treatment remains underutilized in clinical practice. Barriers include anosognosia, a complex treatment landscape, limited evidence-based guidelines, and variable access to care. In February 2025, 11 North American HD specialists and members of the Huntington Study Group (HSG) Motor Treatment Task Force, who collectively care for ∼1500 people with HD (PwHD) convened to discuss current practices and challenges in the pharmacologic treatment of chorea. Insights were supplemented by responses to a long-form questionnaire distributed via email. Attendees and respondents described practical approaches to assessing chorea, engaging care partners, and setting goal-oriented treatment plans. This review draws on collective experience to highlight practical, real-world strategies for the evaluation and treatment of HD chorea. The two most common medication classes used to suppress chorea are vesicular monoamine transporter 2 (VMAT2) inhibitors and antipsychotics. Individualized titration, regular patient and care partner feedback, and functional, rather than purely motor-based, assessments are key to optimizing therapy. By integrating pharmacologic therapy with multidisciplinary care and holistic, goal-oriented communication about the impact of chorea, clinicians can meaningfully improve safety, independence, and quality of life for individuals and families affected by HD.



Neurology Abstracts

  • 4/23/2026 7:00 AM

    Introduction: Mitochondrial-derived microvesicles (MDVs) enriched with mitochondrial components are emerging as important mediators of intercellular communication, particularly in tissues with high metabolic demands. Schwann cells (SCs) play a vital role in supporting metabolic homeostasis and axonal function. Mitochondrial dysfunction in SCs contributes to the pathogenesis of diabetic peripheral neuropathy (DPN). However, the specific role of SC-derived MDVs (SC-MDVs) in DPN remains elusive. Methods: SC-MDVs and SC-exosomes were isolated from SC-conditioned media via ultracentrifugation and characterized with nanoparticle tracking analysis (NTA), transmission electron microscopy, and immunoblotting. Mitochondrial function within SC-MDVs was assessed by measuring mitochondrial membrane potential (ΔΨm), ATP, and reactive oxygen species (ROS) levels. Primary DRG neurons were cultured in a microfluidic device. Results: NTA showed that the size of SC-MDVs (200-400 nm) was larger than the size of exosomes (30-150 nm). Flow cytometry analysis revealed that SC-MDVs were enriched with mitochondrial proteins and functional mitochondria. Compared to SC-MDVs from SCs cultured under normal glucose level, SC-MDVs isolated from high glucose (HG, 25 mM) exhibited a 50% reduction in mitochondrial biogenesis protein and loss of ΔΨm (p< 0.01), 40% decrease in ATP production (p< 0.01), and 2.1-fold increased ROS content (p< 0.001). Argonaute 2 (Ago2), a core component of RNA-induced silencing complex, regulates the loading of miRNAs into EVs, enabling repression of target mRNAs in recipient cells. Notably, MDVs isolated from the sera of diabetic patients and from high-fat diet (HFD)/streptozotocin (STZ)-induced diabetic mice exhibited a 60–70% reduction in Ago2 expression. Furthermore, treatment of DRG neurons with dysfunctional MDVs derived from SC-specific Ago2-deficient sciatic nerve tissues resulted in a marked suppression of axonal growth (p < 0.01). In contrast, administration of naïve SC-derived MDVs restored axonal mitochondrial function, increased ATP levels by 2.5-fold (p < 0.01), and reduced HG-induced activation of the NLRP3 (NOD-like receptor protein 3) inflammasome by 55%, as assessed by immunoblotting in DRG neurons under HG conditions, suggesting that downregulation of Ago2 may disrupt the function of SC-MDVs. Summary/Conclusion: Our results show that SC-MDVs function as critical mediators of SC-axon metabolic coupling, and hyperglycemia-induced SC-MDVs could contribute to DPN pathogenesis.

  • 3/1/2026 8:00 AM

    INTRODUCTION: Current therapies for acute ischemic stroke (AIS) fail to address microvascular dysfunction. Lamiflo™, a high-molecular-weight drag-reducing polymer (DRP), enhances microvascular flow via hemodynamic modulation. We tested its efficacy when given 1 or 3 hours after transient middle cerebral artery occlusion (tMCAO). METHODS: Wistar rats underwent 3.5-hour monofilament tMCAO. Lamiflo™ (5 ppm) or saline was administered i.v. at 1 or 3 h (n=5/group). At 3.5 h, Laser Speckle Contrast Imaging (LSCI) was used to evaluate cortical microcirculation. On day 1, neurobehavior was evaluated, followed by post-mortem infarct volume (TTC), and blood-brain barrier (BBB) permeability (Evans Blue) determination. RESULTS: tMCAO progressively impaired cortical microcirculation, leading to tissue ischemia and BBB disruption. Lamiflo™ improved cortical microcirculation via collateral flow enhancement, thereby reducing infarct volume, BBB degradation, leading to improved functional outcome (all p< 0.05). DRP efficacy reduced with the time of application from 1 h to 3 hours after tMCAO, but remained significant. CONCLUSIONS: Lamiflo™ preserves cerebral microcirculation via collateral flow enhancement, limits infarct and BBB damage, and improves outcomes up to 3 h post-tMCAO, supporting its use as a microcirculatory adjunct in AIS.

  • 3/1/2026 8:00 AM

    INTRODUCTION: Brainstem seizures are a rare phenomenon of brainstem stroke possibly resulting from injury to the proposed centrencephalic system. We observed hypoxic respiratory arrest resulting from these brainstem seizures involving tonic spasm of the diaphragm, a complication to our knowledge not previously reported in the literature. DESCRIPTION: A 69-year-old female presented with acute onset of altered mental status and left-sided weakness. CT angiography showed basilar artery thrombosis. The patient was taken for a thrombectomy, but recanalization could not be achieved. An MRI of the brain demonstrated acute infarction of the pons and bilateral cerebellum. Several days later, she had a sudden episode of acute hypoxia with oxygen saturation dropping to as low as 30. On evaluation, the patient appeared to have tonic spasms of her respiratory muscles resulting in complete respiratory arrest with loss of tidal volume, refractory hypoxemia, hemodynamic instability, and limited chest wall movement with manual ventilation. She required increased sedation which allowed the team to effectively ventilate her along with improvement in her hemodynamics and oxygen saturation. She developed another tonic spasm which was refractory to additional doses of sedation. Cisatracurium was administered which aborted this phenomenon resulting in a rapid clinical improvement. The patient continued on high doses of sedation and was started on carbamazepine as daily preventative therapy. After this treatment strategy was initiated, the patient was not observed to have any further episodes. DISCUSSION: Brainstem seizures with diaphragmatic tonic spasm represent a rare complication of basilar artery occlusion. This phenomenon is not well described in literature making it difficult to manage, ultimately leading to high-risk clinical scenarios such as hypoxic respiratory arrest. Our case highlights a dual pronged approach to management including abortive therapy, utilizing high doses of sedation and neuromuscular blockade, in conjunction with a preventative strategy with an antiepileptic drug, carbamazepine. Further studies are required to identify the underlying etiology of diaphragmatic tonic spasms and treatment guidelines in order to prevent patient harm.

  • 3/1/2026 8:00 AM

    INTRODUCTION: Use of direct oral anticoagulants for atrial fibrillation and venous thromboembolism can cause intracranial bleeding. While guidelines recommend andexanet alfa for reversing factor Xa inhibitors, its high cost and thrombotic risk have led to off-label use of 4F-PCC, despite limited comparative data. This quality improvement study evaluates the effectiveness of andexanet alfa vs. 4F-PCC for bleeding control in clinical practice. METHODS: We conducted a retrospective review (Oct 2020–Oct 2024) of patients who: 1) had a head CT showing intracranial hemorrhage, 2) were on a FXa inhibitor, and 3) received 4F-PCC or andexanet alfa. Demographics, clinical severity (NIH Stroke Scale [NIHSS], Glasgow Coma Scale [GCS]), hemorrhage features, treatment timing, and discharge outcomes were compared. Hemorrhage volumes were measured with Synapse imaging software. Primary outcomes were absolute and percent hemorrhage volume change, significant hemorrhage growth (>6 mL or >33%), and neurological deterioration (≥2-point GCS decrease or ≥4-point NIHSS increase). RESULTS: Of 134 eligible patients, 43 received andexanet alfa and 91 received 4F-PCC. Traumatic bleeds accounted for 64% of cases. Common diagnoses included traumatic subdural hemorrhage (n=31), spontaneous intracerebral hemorrhage (n=30), and traumatic multicompartmental hemorrhage (n=28). Mean age was 78 years, baseline GCS was 13, and mean baseline hemorrhage volume was 43 mL (range: 0.1–284 mL). Age, gender, race, and door-to-needle times were similar between groups. Andexanet alfa patients had higher NIHSS (20 vs. 13, p=0.004) and lower GCS (10 vs. 11, p=0.019) on admission. Mean absolute and percent volume changes were similar; however, more patients on andexanet alfa had significant hemorrhage growth (42% vs. 23%, p=0.029). Neurological deterioration rates were comparable. Ischemic or thromboembolic complications were similarly low for andexanet alfa (2%) and 4F-PCC (4%). CONCLUSIONS: In this real-world analysis, andexanet alfa was linked to a higher risk of significant intracranial hemorrhage growth than 4F-PCC, despite similar rates of neurological deterioration, thromboembolic events, functional disability, and mortality. 4F-PCC may serve as a clinically viable alternative for reversing FXa inhibitor anticoagulation in intracranial hemorrhage.

  • 1/29/2026 8:00 AM

    Introduction: Vascular dementia (VaD) induces white matter (WM) damage, however, the molecular mechanisms underlying WM dysfunction and VaD remain unclear. The present study investigated the role of miR-219 in VaD-induced WM damage. Methods: MiR-219 mediates oligodendrocyte progenitor cell (OPC) function. To investigate the potential role of miR-219 in VaD-induced WM damage, we generated an inducible transgenic mouse line with specific ablation of miR-219 in oligodendrocyte progenitor cells (NG2-CreERT2; miR-219flox; Tau/GFP, miR-219 KO). VaD was induced by intracarotid administration of cholesterol crystals to provoke multiple microinfarcts (MMI) in mice. Cognitive and depression-like behaviors were evaluated by the forced swim, Morris water maze, and passive avoidance tests conducted at 21-30 days post MMI. Results: RT-PCR confirmed a significant down regulation of miR-219 in the WM of miR-219 KO mice compared to WT mice. Immunohistochemistry revealed that wild-type MMI mice (WT+MMI) significantly reduced NG2+ OPCs and diminished myelin basic protein (MBP) in the corpus callosum (CC). However, compared to WT-MMI, miR-219 KO MMI mice had significant reduction of NG2+ OPCs and MBP+ myelin (p<0.01, n=3-5/group). Western blot showed that miR-219 KO+MMI mice significantly reduced marker proteins of mature oligodendrocytes (OLs) including APC (adenomatous polyposis coli) by 67%, CNPase by 47%, and MBP by 43% (p<0.05 vs WT+MMI, n=3/group). RNA-seq data revealed that deregulated genes in miR-219 KO+MMI mice were highly associated with OPC generation and differentiation, myelination, and myelin sheath compared to genes in WT+MMI mice. Downregulation of miR-219 increased its target genes of PDGFRα (Platelet-derived growth factor receptor alpha) and Foxj3 (Forkhead box J3) in the CC and striatum, which are known to regulate OPC function. Additionally, WT+MMI mice exhibited significantly increased escape latency in the passive avoidance test, reduced time spent in the target platform quadrant in the Morris water maze test, and decreased active time in the forced swim test compared to sham controls, indicating cognitive and behavioral deficits. MiR-219 KO+MMI mice exhibited an exacerbated cognitive decline and increased depression-like behavior compared to WT+MMI mice. Conclusions: Ablation of miR-219 in OPCs aggravates MMI- induced WM damage and cognitive and behavioral deficits, suggesting that therapy targeting augmentation of miR-219 can reduce VaD-induced WM damage.

  • 1/29/2026 8:00 AM

    Background: Stroke and cardiac arrest are major contributors to global mortality. The development of cardiac complications such as cardiac arrest, myocardial infarction, and arrhythmias is higher in people who experience stroke, and these complications are more pronounced in individuals with pre-existing heart conditions. The aim of this study is to assess long-term mortality trends in people who have had a stroke and cardiac arrest in the U.S. and to discern populations at highest risk. Methods: Mortality rates were obtained from the CDC WONDER Database among adults aged 45 years and older who had a stroke (ICD-10 code 164) and cardiac arrest (ICD-10 code 146) from 1999 to 2023. Age-adjusted mortality rates (AAMRs) per 100,000 population and annual percent change (APC) were calculated via Joinpoint regression with a 95% confidence interval (CI), analyzing trends by year, race, gender, ethnicity, and region. Results: There were a total of 385,887 stroke and cardiac arrest-related deaths between 1999 and 2023 among adults aged ≥ 45 years. Overall AAMR followed a decreasing trend over the years, from 23.9 in 1999 to 12.9 in 2009 (APC: -6.28; 95% CI: -6.97 to -5.58), then falling to 6.7 in 2023 (APC: -4.17; 95% CI: -4.78 to -3.55). Males had a persistently higher mortality as compared to females, with AAMRs of 7.6 and 6.0 in 2023, respectively. NH Blacks/African Americans had the highest AAMR, followed by Hispanic/Latino, NH White, and NH American Indian/Alaska Native. Geographically, the Western region had the highest AAMR, followed by the Northeast, the South, and the Midwest. Moreover, metropolitan areas had a higher mortality rate (14.5) compared to non-metropolitan areas (14.0). Conclusion: Our study shows a decreasing trend in stroke and cardiac arrest-related mortality among older adults in the United States from 1999 to 2023. We observed significant demographic and geographic disparities, with higher mortality among men, Blacks/African Americans, individuals in the Western region, and those living in metropolitan areas.

  • 1/29/2026 8:00 AM

    Background: Cerebral hyperperfusion syndrome (CHS) after carotid revascularization procedures, such as carotid artery stenting (CAS) and carotid endarterectomy (CEA), is a well-described and serious complication. Predicting which patients are most likely to experience CHS utilizing transcranial doppler (TCD) ultrasonography remains uncertain. We aimed to conduct a systematic review and meta-analysis in order to assess the diagnostic accuracy of TCD-related parameters in predicting CHS after carotid interventions. Methods: We conducted a systematic search of PubMed, EMBASE, and Web of Science from inception to July 12, 2025, and performed a meta-analysis to evaluate the role of TCD-related parameters obtained pre- and post-intervention in predicting CHS. Articles evaluating the diagnostic accuracy of TCD studies in predicting CHS in adult patient population undergoing CEA or CAS were included. We utilized a bivariate random-effects model to assess the diagnostic accuracy of TCD parameters and performed the review according to the Preferred Reported Items for Systematic and Meta-analyses (PRISMA) guidelines. Results: Of the 3571 initially identified studies, 15 studies of 5160 patients met the inclusion criteria. Pooled analysis demonstrated that a two-fold increase in the mean flow velocity (MFV) of the ipsilateral middle cerebral artery (MCA) following carotid intervention was associated with an overall sensitivity of 56% (95% confidence interval [CI], 31%-79%, I2=66.2%) and specificity of 93% (95% CI, 86%-96%, I2=66.2%73.4%) for predicting CHS. Moreover, a two-fold increase of ipsilateral peak systolic velocity (PSV) of the MCA demonstrated sensitivity of 54% (95% CI, 26%-79%, I2=46.8%) and specificity of 97% (95% CI, 90%-99%, I2=72.1%). Across the studies, negative predictive value ranged between 95-100% for the aforementioned metrics. A one-fold increase in MCA MFV demonstrated a sensitivity of 88% (95% CI, 68%-96%) and specificity of 81% (95% CI, 74%-86%). In subgroup analysis restricted to patients undergoing CEA, a two-fold increase in MCA MFV yielded sensitivity of 88% (95% CI, 68%-96%) and specificity of 92% (95% CI, 86%-96%). Conclusions: After carotid revascularization procedure, absence of a two-fold increase in MCA MFV or PSV on TCD strongly indicates that CHS is unlikely to occur. However, the modest sensitivity reduces the usefulness of this technique as an early screening tool.

Information for Applicants
Interested in applying to one of our programs? 

Cookie Consent

We use cookies to improve your website experience. By using this site, you agree to our Terms of Use. Read our Internet Privacy Statement  to learn what information we collect and how we use it.

Accept All
Dismiss